Acutaas Chemicals Limited

rs,

rat, India. November 9, 2023 To, The Listing Department, BSE LIMITED, Phiroze Jeejeebhoy Towers, Dalal Street, Fort © Mumbai- 400 001 . To, The Listing Department National Stock Exchange of

17%

years – Key Metrics ➢ Shareholder Information 3 Management Commentary “I am pleased to report a 17% YoY growth, with a revenue from operations of Rs. 172 crores for the quarter, despite facing downwa

Rs. 172 crore

Management Commentary “I am pleased to report a 17% YoY growth, with a revenue from operations of Rs. 172 crores for the quarter, despite facing downward pricing pressures. Even as we navigated the low demand la

8%

d half of FY24. On the business front, Advance Pharmaceutical business delivered steady growth of ~8% YoY, even as for one product, a global customer delayed the launch in certain markets impacting our

72%

ing revenue visibility for the coming years. On the Speciality chemicals side, we delivered strong 72% growth YoY, driven by robust volume. The launch of a new UV Observer product is set to enhance our

16 MW

tment towards sustainability and operational cost reduction, the board has approved investment in a 16 MW solar power plant which along with already work in progress 5 MW solar power plant will nullify our

5 MW

oard has approved investment in a 16 MW solar power plant which along with already work in progress 5 MW solar power plant will nullify our electricity expense once fully operational. Deferment in produc

25%

ugh we are expecting to deliver robust H2 FY24, overall, we are modifying our growth target from 22-25% for the full year to 18-22% growth for FY24.” 4 Mr. Naresh Patel Executive Chairman and Managing

22%

ver robust H2 FY24, overall, we are modifying our growth target from 22-25% for the full year to 18-22% growth for FY24.” 4 Mr. Naresh Patel Executive Chairman and Managing Director Revenue for Q2FY2

Rs. 1,724

for FY24.” 4 Mr. Naresh Patel Executive Chairman and Managing Director Revenue for Q2FY24 (Mn) Rs. 1,724 17% EBIDTA for Q2FY24 (Mn) Rs. 248 (12%) Adj. PAT for Q2FY24 (Mn) Rs. 147 (23%) YoY YoY YoY

Rs. 248

ive Chairman and Managing Director Revenue for Q2FY24 (Mn) Rs. 1,724 17% EBIDTA for Q2FY24 (Mn) Rs. 248 (12%) Adj. PAT for Q2FY24 (Mn) Rs. 147 (23%) YoY YoY YoY Q2FY24 Financial Highlights ➢ Revenu

12%

man and Managing Director Revenue for Q2FY24 (Mn) Rs. 1,724 17% EBIDTA for Q2FY24 (Mn) Rs. 248 (12%) Adj. PAT for Q2FY24 (Mn) Rs. 147 (23%) YoY YoY YoY Q2FY24 Financial Highlights ➢ Revenue fr

“• Signed a new contract for additional advanced intermediate taking total product under CDMO contract to 3 products • On track to start the production from Q4FY24 onwards from Ankleshwar Unit ➢ Specialty Chemicals • Received orders for a UV Observer product used in Paint Industry.”

“Expect commercial production to start from Q3 FY24 ➢ Electrolyte additives update • Advanced stages of negotiation of contract with couple of customers.”

“facility ❑ Consists of 26 stainless steel and glass reactors with fully dedicated lines for paraben, PHBA production ❑ The new plant will be set up at Ankleshwar ❑ Equipped with state of art ETP with zero liquid site to cater to growing demand of Advance Pharmaceutical Intermediates discharge solutions ❑ Unused 15,830 sq mtrs land available to explore brownfield expansion opportunities 20 Superior R&D Capabilities R&D Lab 1 Technology 2 23,681 sq.”

“Currently, the old plant at Ankleshwar is being demolished and the new plant will be built on this site.”

“The Capex will be funded through a mix of General Corporate funds of IPO proceeds, internal accruals, and debt.”

Fermion contract

1

For more information please contact

1

Fermion contract

• Signed a new contract for additional advanced intermediate taking total product under CDMO contract to 3 products • On track to start the production from Q4FY24 onwards from Ankleshwar Unit ➢ Specialty Chemicals • Received orders for a UV Observer product used in Paint Industry. Expect commercial production to start from Q3 FY24 ➢ Electrolyte additives update • Advanced stages of negotiation of contract with couple of customers. ➢ Capex Update • Machinery installation in progress in block-1 at Ankleshwar unit • Started the recruitment process for the new facility. On track to commence the production activity in Q4 FY24 ➢ Baba Fine Chemicals Acquisition Update • Completed acquisition of majority partnership stake in Baba Fine Chemicals during the quarter 6 Q2FY24 Financial Performance – Key Metrics YoY Growth 7.7% 1,249 1,346 Revenue from Operations (Rs Mn) 71.4% Q2FY23 Q2FY24 220 378 Advance Intermediates Specialty Chemicals EBITDA & EBITDA Margin (Rs Mn) PAT (Rs Mn) 300 280 260 240

For more information please contact

Ami Organics Limited Ekta Srivastava Company Secretary & Compliance Officer cs@amiorganics.com Ernst & Young Rahul Thakur rahul.thakur@in.ey.com Advait Bhadekar advait.bhadekar@in.ey.com © 2020 Ami Organics Limited, All Rights Reserved. 44